The response to erlotinib in non-small cell lung cancer (NSCLC) LU2512 (EGFR wildtype) PDX in vivo (TGI 19.87% with 5mg/kg IP weekly dose), PDXO in vitro (IC50 value of 21.04μM and 65.19% maximum inhibition) and PDXO xenograft in vivo (53% TGI with 5mg/kg IP weekly dose) was comparable with poor sensitivity to erlotinib reflected in all three scenarios (Fig 3c). This evidence concerns the gene EGFR and non-small cell lung carcinoma.